

Remarks:

Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

							Status	: Resubmissi	on
and Clearing Limited									
ImmuneOnco Biopharmac	euticals (Sh	nanghai) Inc. (A joint s	stock com	npany inco	orporated in the Pe	ople's Republic of Ch	nina with lim	nited liability)	
05 June 2025									
rised / Registered Share	e Capital								
Ordinary shares		Type of shares	Н			Listed on the Exchang	ge (Note 1)	Yes	
01541		Description	H Share	:S		1			
	Number of	f authorised/registere	d shares		Par valu	е	Auth	norised/registe	red share capital
Balance at close of preceding month		382,163,299 RMB			1	RMB	382,163,299		
Increase / decrease (-)		14,114,000			3		RMB	14,114,00	
Balance at close of the month		396,277,30			1 RMB		RMB	396,277,305	
			,						1
Ordinary shares	Type of shares		Other ty	er type (specify in description) Listed on the Exchan		ge (Note 1)	No		
N/A	Description Unlis		Unlisted	d shares					
	Number of	f authorised/registere	d shares		Par valu	е	Auth	norised/registe	red share capital
Balance at close of preceding month		25,144,396		RMB :		RMB	25,144,39		
Increase / decrease (-)		-14,114,006			6		RMB	-14,114,00	
Balance at close of the month		11,030,390		RMB	RMB :		RMB		11,030,390
-i	ImmuneOnco Biopharmac 05 June 2025 ised / Registered Share Ordinary shares 01541 ing month th Ordinary shares N/A	ImmuneOnco Biopharmaceuticals (Shape 2025 ised / Registered Share Capital Ordinary shares 01541 Number of the Capital shape of the	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint solution of June 2025 ised / Registered Share Capital Ordinary shares O1541 Description Number of authorised/registere of shares In part of shares Ordinary shares Ordinary shares Type of shares Type of shares Description Number of authorised/registere of shares N/A Description Number of authorised/registere of shares N/A Description Number of authorised/registere of shares N/A Description Number of authorised/registere of shares Ordinary shares N/A Description	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock con 05 June 2025 ised / Registered Share Capital Ordinary shares Description Number of authorised/registered shares 14,114,006 Type of shares Ordinary shares Type of shares Ordinary shares Type of shares Other ty N/A Description Unlisted Number of authorised/registered shares Other ty N/A Description Unlisted Number of authorised/registered shares In the shares of authorised/registered shares Other ty N/A Description Unlisted Ordinary shares Other ty N/A Description Ordinary shares Other ty N/A Description Ordinary shares Other ty N/A Description Ordinary shares	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock company inco 05 June 2025 ised / Registered Share Capital Ordinary shares Number of authorised/registered shares Ing month Ordinary shares Type of shares Number of authorised/registered shares Ing month Type of shares Number of authorised/registered shares Type of shares Other type (specification) Number of authorised/registered shares Number of authorised/registered shares Number of authorised/registered shares Ing month Description Unlisted shares Ing month Description Page 14,114,006	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock company incorporated in the Percost June 2025 ised / Registered Share Capital Ordinary shares Type of shares Number of authorised/registered shares Par value and the shares Ordinary shares Number of authorised/registered shares Type of shares Other type (specify in description) N/A Description Unlisted shares Par value and the Percost Share Share Share Share Share Shares Number of authorised/registered shares Par value Shares Par value Shares Par value Shares Number of authorised/registered shares Par value Shares	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock company incorporated in the People's Republic of Ch 05 June 2025 ised / Registered Share Capital Ordinary shares Type of shares Number of authorised/registered shares Par value 14,114,006 Type of shares Par value 10,277,305 Type of shares Type of shares Ordinary shares Type of shares Other type (specify in description) Listed on the Exchange Shares N/A Description Unlisted shares Number of authorised/registered shares Par value 10,277,305 Par value 11,277,305 Par value 12,277,305 Par value 13,277,305 Par value 14,277,305 Par value 15,277,305 Par value 16,277,305 Par value	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock company incorporated in the People's Republic of China with Iim 05 June 2025 ised / Registered Share Capital Ordinary shares Type of shares H Listed on the Exchange (Note 1) 01541 Description H Shares Number of authorised/registered shares Par value Authorised	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (A joint stock company incorporated in the People's Republic of China with limited liability) 05 June 2025 iseed / Registered Share Capital Ordinary shares Type of shares H Listed on the Exchange (Note 1) Yes 01541 Description H Shares Number of authorised/registered shares Par value Authorised/registered growth 382,163,299 RMB 1 RMB th 396,277,305 RMB 1 RMB Ordinary shares Type of shares Other type (specify in description) Listed on the Exchange (Note 1) No N/A Description Unlisted shares Number of authorised/registered shares Par value Authorised/registered shares

Total authorised/registered share capital at the end of the month: RMB

Page 1 of 12 v 1.1.1

407,307,695

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the "Company") has received the filing notice from the China Securities Regulatory Commission and the approval from The Stock Exchange of Hong Kong Limited (the "Stock Exchange") of the conversion of 14,114,006 unlisted shares of the Company (the "Unlisted Shares") into H shares of the Company (the "H Shares") and their listing on the Stock Exchange, as disclosed in the announcements of the Company dated 14 May 2025 and 24 April 2025 respectively. The relevant conversion was completed on 14 May 2025, as disclosed in the announcement of the Company dated 14 May 2025. The listing of the converted H Shares on the Stock Exchange commenced on 15 May 2025.

The opening balance as at 30 April 2025 was 382,163,299 H Shares and 25,144,396 Unlisted Shares, amounting to a total of 407,307,695 issued shares of the Company. Following the conversion, the H Shares increased by 14,114,006 shares, while the Unlisted Shares decreased by 14,114,006 shares. The total number of issued shares of the Company after the conversion remains unchanged, comprising 396,277,305 H Shares and 11,030,390 Unlisted Shares. As the Company is incorporated in the People's Republic of China, the concept of "authorized share capital" is not applicable, and the above information refers to the "registered share capital" of the Company.

Page 2 of 12 v 1.1.1

II. Movements in Issued Shares and/or Treasury Shares

1. Class of shares	Ordinary shares	3	Type of shares	Н		Listed on the Exchan	ge (Note 1)	Yes	
Stock code (if listed)	01541		Description	H Shar	H Shares				
		Number of issued shares (excluding treasury shares)			Number of treasury shares		Total number of issued shares		
Balance at close of preceding month		382,163,299		0		382,163,299			
Increase / decrease (-)		14,114,006		0					
Balance at close of the month			396,277,305		0		396,277,305		
2. Class of shares	ordinary shares		Type of shares	Other type(specify in description)		Listed on the Exchan	ge (Note 1)	No	
Stock code (if listed)	N/A		Description Unliste		d shares				
	Number of issued shares (excluding treasury shares)			Number of treasury shares		Total number of issued shares		issued shares	
Balance at close of preceding month			25,144,396		0		25,144,396		
Increase / decrease (-)	/ decrease (-) -14,13		114,006	0					
Balance at close of the mo	onth		11,030,390		0		11,030,390		

Page 3 of 12 v 1.1.1

III. Details of Movements in Issued Shares and/or Treasury Shares

(A). Share Options (under Share Option Schemes of the Issuer) Not applicable

Page 4 of 12 v 1.1.1

Not applicable

Page 5 of 12 v 1.1.1

Not applicable

Page 6 of 12 v 1.1.1

Not applicable

(D). Any other Agreements or Arrangements to Issue Shares of the Issuer, including Options (other than Share Option Schemes)

Page 7 of 12 v 1.1.1

(E). Other Movements in Issued Shares and/or Treasury Shares

1. Class of shares	Ordinary shares	Тур	e of shares	Н		Listed on the Exchange (No		Yes		
Stock code (if listed)	01541 Description			H Shares					<u>'</u>	
Events 1). Conversion of 14,114,006 Unlisted Shares into H Shares on 14 May 2025		At pr	ice (if applicable)	Date of event (Note 2)	General Meeting approval date (if applicable)	shares (excluding treasury shares) during the month	Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)		Number of shares re repurchased for cano not yet cancelled as the month (No	cellation but at close of
		Currenc	y Amount			pursuant thereto (E1)			the month (Note 3)	
				14 May 2025		14,114,006				0
2. Class of shares	Ordinary shares	Тур	e of shares	Other type (Pleas	se specify)	Listed on the Exchange (No	ote 1)		No	
Other type (Please specify)	Unlisted Shares	,			'					
Stock code (if listed)	N/A	Desc	cription							
Events		At pr	ice (if applicable)	Date of event (Note 2)	General Meeting approval date (if applicable)	Increase/ decrease (-) in issued shares (excluding treasury shares) during the month pursuant thereto (E1)	Increase/ decrease (-) in treasury shares during the month pursuant thereto (E2)		Number of shares redeemed or repurchased for cancellation but not yet cancelled as at close of the month (Note 3)	
		Currenc	y Amount			, , ,				
1). Conversion of 14,114,006 Unlis 14 May 2025	sted Shares into H Shares on			14 May 2025		-14,114,006				0
	Incre	ease/ decreas	e (-) in issued s	hares (excluding t	reasury shares)	:14,			es H (EE1)	
	Incre	ease/ decreas	e (-) in issued s	hares (excluding t	reasury shares)	: -14,	114,006 Ordin (EE1		es Unlisted Shar	es
			Increas	se/ decrease (-) in	treasury shares	:	Ordin	ary share	es H (EE2)	
			Increas	se/ decrease (-) in	treasury shares	:	Ordin (EE2		es Unlisted Shar	es
Remarks:							•			
The conversion of 14,114,00 as disclosed in the announce				L4 May 2025, and t	the listing of the	converted H Shares on the	Stock Exchange	had comr	menced on 15 M	ay 2025,
Total increase/ decre	ase (-) in issued shares	(excluding tre	easury shares) (during the month (i	i.e. Total of AA1	. to EE1):	14,114,006	Ordina	ry shares H	
Total increase/ decre	ase (-) in issued shares	(excluding tre	easury shares) o	during the month (i	i.e. Total of AA1	to EE1):	-14,114,006	Ordina Shares	ry shares Unliste	d

Page 8 of 12 v 1.1.1

Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):	Ordinary shares H
Total increase/ decrease (-) in treasury shares during the month (i.e. Total of AA2 to EE2):	Ordinary shares Unlisted Shares

Page 9 of 12 v 1.1.1

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

Page 10 of 12 v 1.1.1

	٧.	Confirmations	Not applicable
--	----	---------------	----------------

Submitted by: Guan Mei

Title: Executive Director and Joint Company Secretary

(Director, Secretary or other Duly Authorised Officer)

Page 11 of 12 v 1.1.1

Notes

- 1. The Exchange refers to The Stock Exchange of Hong Kong Limited.
- 2. In the case of repurchase of shares (shares repurchased and cancelled) and redemption of shares (shares redeemed and cancelled), "date of event" should be construed as "cancellation date".

In the case of repurchase of shares (shares held as treasury shares), "date of event" should be construed as "date on which shares were repurchased and held by the issuer in treasury".

- 3. The information is required in the case of repurchase of shares (shares repurchased for cancellation but not yet cancelled) and redemption of shares (shares redeemed but not yet cancelled). Please state the number of shares repurchased or redeemed during the month or in preceding month(s) but pending cancellation as at close of the month as a negative number.
- 4. Items (i) to (viii) are suggested forms of confirmation. The listed issuer may amend the item(s) that is/are not applicable to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, or the treasury shares sold or transferred, no further confirmation is required to be made in this return.
- 5. "Identical" means in this context:
 - the securities are of the same nominal value with the same amount called up or paid up;
 - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
 - they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.

Page 12 of 12 v 1.1.1